An economic evaluation of antihypertensive therapies based on clinical trials

Clinics

Volumn 67, Issue 1, 2012, Pages 41-48

  Tsuji, Rosana Lima Garcia ^a   da Silva, Giovanio Vieira ^a   Ortega, Katia Coelho ^a   Berwanger, Otávio ^a   Mion, Décio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antihypertensive drugs; Cost effectiveness; Hypertension; Pharmacoeconomics

Indexed keywords

EID: 84855995438     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(01)07     Document Type: Article

References (17)

1. Dunn EC, Small RE. Economics of antihypertensive in the elderly. Drugs Aging. 2001;18:515-25, doi: 10.2165/00002512-200118070-00005.
2. Kiiskinen U, Vartiainen E, Puska P, Aromaa A. Long-term cost and lifeexpectancy consequences of hypertension. J Hypertens. 1998;16:1103-12, doi: 10.1097/00004872-199816080-00004.
3. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics. 2004;22:907-28, doi: 10.2165/00019053-200422140-00002.
4. IV Brazilian Guidelines on Hypertension. Arq Bras Cardiol. 2010;95(suppl 1):1-51.
5. Mion D Jr, Ortega KC. Should we spend less or control a greater percentage of hypertensive patients? Sao Paulo Med J. 2002;120:99.
6. Dias da Costa JS, Fuchs SC, Olinto MT, Gigante DP, Menezes AM, Macedo S, et al. Cost-effectiveness of hypertension treatment: a population-based study. Sao Paulo Med J. 2002;120:100-4.
7. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53, doi: 10.1097/00004872-200306000-00001.
8. Materson BJ. Combination therapy as the initial drug treatment for hypertension: when is it appropriate?. Am J Hypertens. 2001;14:293-5, doi: 10.1016/S0895-7061(00)01259-0.
9. Ortega KC, Gusmão JL, Pierin AM, Nishiura JL, Ignez EC, Segre CA, et al. How to avoid discontinuation of anthypertensive treatment. The experience in São Paulo. Clinics. 2010;65(9):857-63.
10. Chen RS, Lapuerta P. Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents. Curr Hypertension Reports. 2000;2:525-9, doi: 10.1007/s11906-996-0036-5.
11. Zanchetti A. Antihypertensive therapy: how to evaluate the benefits. Am J Cardiol. 1997;79:3-8, doi: 10.1016/S0002-9149(97)00264-6.
12. Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens. 2001;19:149-55, doi: 10.1097/00004872-200101000-00020.
13. Hilleman DE, Mohiuddin SM, Lucas BD Jr, Stading JA, Stoysich AM, Ryschon K. Cost-minimisation analysis of initial antihypertensive therapy in patients with mild to moderate essential diastolic hypertension. Clin Ther. 1994;16:88-102.
14. Ramsay LE, Yeo WW, Jackson PR. Thiazide diuretics: first-line therapy for hypertension. J Hypertens. 1992;10:S29-S32, doi: 10.1097/00004872-199200103-00005.
15. Moser M. The cost of treating hypertension. Can we keep it under control without compromising the level of care? Am J Hypertens. 1998;11:120S-127S, doi: 10.1016/S0895-7061(98)00106-X.
16. Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens. 1998;11:618-29, doi: 10.1016/S0895-7061(97)00488-3.
17. Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens. 2001;19:S34-S40.